
ELDN
Eledon Pharmaceuticals Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.8195
Open
3.700
VWAP
--
Vol
1.56M
Mkt Cap
193.42M
Low
3.090
Amount
--
EV/EBITDA(TTM)
--
Total Shares
38.51M
EV
91.89M
EV/OCF(TTM)
--
P/S(TTM)
--
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-0.253
-73.21%
--
--
-0.257
-19.79%
--
--
-0.232
-78.14%
Estimates Revision
The market is revising No Change the revenue expectations for Eledon Pharmaceuticals, Inc. (ELDN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -1.22%.
EPS Estimates for FY2025
Revise Downward

-21.44%
In Past 3 Month
Stock Price
Go Down

-1.22%
In Past 3 Month
6 Analyst Rating

178.64% Upside
Wall Street analysts forecast ELDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELDN is 9.00 USD with a low forecast of 8.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy

178.64% Upside
Current: 3.230

Low
8.00
Averages
9.00
High
10.00

178.64% Upside
Current: 3.230

Low
8.00
Averages
9.00
High
10.00
Craig-Hallum
NULL -> Buy
initiated
$12
2025-07-25
New
Reason
Craig-Hallum
Price Target
$12
2025-07-25
New
initiated
NULL -> Buy
Reason
Craig-Hallum initiated coverage of Eledon Pharmaceuticals with a Buy rating and $12 price target.
Craig-Hallum
initiated
$12
2025-07-25
New
Reason
Craig-Hallum
Price Target
$12
2025-07-25
New
initiated
Reason
As previously reported, Craig-Hallum initiated coverage of Eledon Pharmaceuticals with a Buy rating and $12 price target. Eledon is developing tegoprubart to address the need for a new SOC in immunosuppression for kidney transplant patients, as current therapies cause kidney damage as a side effect, contributing to kidney graft failure after 10-15 years. The firm notes Tegoprubart's advantages support its potential to be the new SOC for kidney transplantation, which is a multi-billion dollar market opportunity, and it has broad utility in other organ transplant settings. Craig-Hallum sees opportunity for significant share appreciation with upcoming data catalysts in kidney transplantation including a Phase Ib update at WTC on August 6th, with readthrough to the Phase II topline readout in November, which represents a major de-risking event.
H.C. Wainwright
Yi Chen
initiated
$9
2025-06-19
Reason
H.C. Wainwright
Yi Chen
Price Target
$9
2025-06-19
initiated
Reason
H.C. Wainwright analyst Yi Chen assmed coverage of Eledon Pharmaceuticals with a Buy rating and $9 price target. Eledon is a clinical-stage biotechnology company focused on the development of an antibody targeting the CD40 ligand to prevent the rejection of transplanted organs and to treat neuroinflammation, the analyst tells investors in a research note. The firm says interim results from the Phase 1b trial demonstrated the company's lead candidate tegoprubart is generally safe and well tolerated in patients undergoing de novo kidney transplantation.
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$16
2024-11-20
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$16
2024-11-20
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Eledon Pharmaceuticals Inc (ELDN.O) is -3.97, compared to its 5-year average forward P/E of -2.10. For a more detailed relative valuation and DCF analysis to assess Eledon Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-2.10
Current PE
-3.97
Overvalued PE
-0.66
Undervalued PE
-3.54
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-1.70
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
5.96
Undervalued EV/EBITDA
-9.36
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
+65.28%
-17.96M
Operating Profit
FY2025Q1
YoY :
-72.51%
-6.50M
Net Income after Tax
FY2025Q1
YoY :
-89.87%
-0.08
EPS - Diluted
FY2025Q1
YoY :
+83.73%
-16.06M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 138.83% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
4
9.4M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ELDN News & Events
Events Timeline
2025-07-09 (ET)
2025-07-09
08:33:19
Sernova enters collaborative research agreement with Eledon Pharmaceuticals

2025-05-14 (ET)
2025-05-14
16:15:59
Eledon Pharmaceuticals reports Q1 EPS (8c), consensus (30c)

2025-01-13 (ET)
2025-01-13
06:25:07
Eledon Pharmaceuticals highlights recent business milestones, 2025 outlook

Sign Up For More Events
Sign Up For More Events
News
6.0
07-14NASDAQ.COMNew Strong Buy Stocks for July 14th
7.5
07-09GlobenewswireSernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes
1.0
06-25NewsfilterEledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City
Sign Up For More News
People Also Watch

AEVA
Aeva Technologies Inc
22.000
USD
+2.37%

CFFI
C&F Financial Corp
66.060
USD
-1.15%

SLN
Silence Therapeutics PLC
5.920
USD
-6.62%

LFCR
Lifecore Biomedical Inc
7.330
USD
-1.35%

BNTC
Benitec Biopharma Inc
11.020
USD
-1.43%

HBB
Hamilton Beach Brands Holding Co
16.740
USD
-7.15%

FHTX
Foghorn Therapeutics Inc
6.500
USD
+5.01%

TLS
Telos Corp
2.850
USD
+0.35%

NWFL
Norwood Financial Corp
24.600
USD
-0.08%
FAQ

What is Eledon Pharmaceuticals Inc (ELDN) stock price today?
The current price of ELDN is 3.23 USD — it has decreased -10.77 % in the last trading day.

What is Eledon Pharmaceuticals Inc (ELDN)'s business?

What is the price predicton of ELDN Stock?

What is Eledon Pharmaceuticals Inc (ELDN)'s revenue for the last quarter?

What is Eledon Pharmaceuticals Inc (ELDN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Eledon Pharmaceuticals Inc (ELDN)'s fundamentals?

How many employees does Eledon Pharmaceuticals Inc (ELDN). have?
